A new treatment that will allow Parkinson’s patients to better control their symptoms will be available in the US in 2025.

The US Food and Drug Administration (FDA) has approved a new treatment that provides 24 -hour relief from the symptoms caused by the disease.

Onapgo therapy is done through a subcutaneous device of continuous drug infusion (dopamine, hydrochloride aposthemin), which helps manage symptoms

Clinical trials showed that the device significantly reduced daily episodes on average 2.47 hours, compared to virtual treatment (0.58 hours).

“This treatment has the ability to change the data by helping us to provide more personalized and effective care to people living with Parkinson’s disease. In addition, as more treatments are approved like this, the need for continuing innovation in the development of drugs and especially those that focus on symptoms control, without having to rely on oral medications are reinforced.“Said Kelley Pope, Executive Director of the Association of Advanced Motor Disorders, in a recent interview with Neurobiologylive.

“As Parkinson’s disease progresses, levodopa treatment often becomes less effective in providing consistent motor control, partly due to gastrointestinal dyskinesia, variable absorption of oral drugs and subsequent pulsating stimulation of dopamine trails” Dr. Stewart Esakson, director of the Parkinson’s Center and Boca Raton’s motor disorders in Florida, who was also one of the clinical trials clinical trial.

“The constant injection of apionmmmine offers onapgo immediately stimulates the post -consistent dopamine receptors without the need for metabolic conversion. In addition, subcutaneous administration of aposthemine bypasses the gastrointestinal system and enters the brain, which can allow more predictable improvement of symptoms, ”he added.

The new approved injection device offers better management of symptoms without the need for surgery. The approval of treatment will also be accompanied by a training program for health professionals.

More than 10 million people around the world – only one million in the US – live with progressive neurodegenerative disorder and uncontrolled movements observed in dyskinesia have a significant impact on quality of life and independence.